Journal
GASTROENTEROLOGY
Volume 156, Issue 7, Pages 2056-2072Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2018.12.038
Keywords
PDAC; Immunity; Clinical Trials; Immunotherapy; Pancreatic Cancer
Categories
Funding
- National Institutes of Health [R01 CA197916, U01 CA224193-01, K12 CA184746-01A1, U01 CA224175-01, U01 CA224146-01]
- Damon Runyon Cancer Research Foundation
- Richard and Susan Smith Family Foundation
- Hale Center for Pancreatic Cancer Research
- Harvard-MIT Bridge Project
Ask authors/readers for more resources
Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second deadliest cancer in the United States by 2025, with 5-year survival at less than 10%. In other recalcitrant cancers, immunotherapy has shown unprecedented response rates, including durable remissions after drug discontinuation. However, responses to immunotherapy in PDAC are rare. Accumulating evidence in mice and humans suggests that this remarkable resistance is linked to the complex, dueling role of the immune system in simultaneously promoting and restraining PDAC. In this review, we highlight the rationale that supports pursuing immunotherapy in PDAC, outline the key barriers that limit immunotherapy efficacy, and summarize the primary preclinical and clinical efforts to sensitize PDAC to immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available